Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aptosyn + Taxotere in NSCLC
NCT00085826Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Exisulind + Docetaxel with Placebo + Docetaxel (2 arms). Primary endpoint: Overall Survival. Started Apr 2001; status: completed.
02
Drugs
exisulind
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00085826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085826.